等待开盘 04-02 09:30:00 美东时间
-0.170
-0.66%
今日重点评级关注:Maxim Group:上调Theriva Biologics评级至"买入",目标价1美元;HC Wainwright & Co.:维持Bicara Therapeutics"买入"评级,目标价从40美元升至42美元
04-01 16:34
Stifel analyst Jonathan Block maintains Trupanion (NASDAQ:TRUP) with a Hold and lowers the price target from $35 to $31.
04-01 00:10
Piper Sandler analyst John Barnidge maintains Trupanion (NASDAQ:TRUP) with a Overweight and lowers the price target from $60 to $45.
02-13 22:34
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Trupanion业绩会实录,以下是2025年第四季度及全年财务业绩回顾摘要: ## 1. 财务业绩 **第四季度业绩表现:** - 总营收:3.769亿美元,同比增长12% - 订阅业务营收:2.614亿美元,同比增长15% - 其他业务营收:1.154亿美元,同比增长5% - 调整后营业收入(AOI):4,500万美元,同比增长20% - 净利润:560万美元(每股0.13美元),去年同期为170万美元(每股0.04美元) - 经营现金流:2,930万美元,去年同期为2,370万美元 - 自由现金流:2,530万美元,去年同期为2,180万美
02-13 12:11
Trupanion (NASDAQ:TRUP) sees FY2026 sales of $1.550 billion-$1.582 billion vs $1.582 billion analyst estimate.
02-13 05:21
Trupanion (NASDAQ:TRUP) sees Q1 sales of $376.000 million-$382.000 million vs $380.484 million analyst estimate.
02-13 05:20
华盛资讯2月13日讯,Trupanion, Inc.公布2025财年Q4业绩,公司Q4营收3.77亿美元,同比增长11.7%,归母净利润0.06亿美元,同比增长240.0%。
02-13 05:17
Trupanion (NASDAQ:TRUP) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.16 by 19.75 percent. This is a 225 percent increase over earnings of $0.04 per share from the same
02-13 05:09
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
今日重点评级关注:Piper Sandler:上调Korro Bio评级至"超配",目标价从11美元升至30美元;Piper Sandler:维持Nurix Therapeutics"超配"评级,目标价从32美元升至35美元
01-30 17:38